QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
NASDAQ:TARA

Protara Therapeutics (TARA) Stock Forecast, Price & News

$3.12
+0.23 (+7.96%)
(As of 05/16/2022 04:00 PM ET)
Add
Compare
Today's Range
$2.89
$3.15
50-Day Range
$2.80
$5.60
52-Week Range
$2.72
$11.10
Volume
11,817 shs
Average Volume
37,591 shs
Market Capitalization
$35.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.1
30 days | 90 days | 365 days | Advanced Chart
Receive TARA News and Ratings via Email

Sign-up to receive the latest news and ratings for Protara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Protara Therapeutics logo

About Protara Therapeutics

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.

Headlines

Recap: Protara Therapeutics Q4 Earnings
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TARA
Employees
31
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$14.41 per share

Profitability

Net Income
$-47.25 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
9,981,000
Market Cap
$35.11 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/05/2022
Today
5/16/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.61 out of 5 stars

Medical Sector

87th out of 1,423 stocks

Biological Products, Except Diagnostic Industry

11th out of 209 stocks

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 1.3 5 -4 -3 -2 -1 -













Protara Therapeutics (NASDAQ:TARA) Frequently Asked Questions

Is Protara Therapeutics a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Protara Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Protara Therapeutics stock.
View analyst ratings for Protara Therapeutics
or view top-rated stocks.

When is Protara Therapeutics' next earnings date?

Protara Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Protara Therapeutics
.

How were Protara Therapeutics' earnings last quarter?

Protara Therapeutics, Inc. (NASDAQ:TARA) announced its quarterly earnings results on Thursday, May, 5th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.77) by $0.19.
View Protara Therapeutics' earnings history
.

What price target have analysts set for TARA?

3 brokerages have issued 1-year price targets for Protara Therapeutics' stock. Their forecasts range from $34.00 to $40.00. On average, they anticipate Protara Therapeutics' share price to reach $37.00 in the next twelve months. This suggests a possible upside of 1,085.9% from the stock's current price.
View analysts' price targets for Protara Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Protara Therapeutics' key executives?
Protara Therapeutics' management team includes the following people:
  • Mr. Jesse Shefferman, Co-Founder, CEO, Pres & Director (Age 50, Pay $1.26M)
  • Dr. Jacqueline Zummo M.B.A., M.P.H., Ph.D., Chief Scientific Operations Officer (Age 41, Pay $626.18k)
  • Mr. Blaine T. Davis, CFO & Sec. (Age 48, Pay $635.31k)
  • Dr. Jathin Bandari M.D., Chief Medical Officer
What other stocks do shareholders of Protara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Protara Therapeutics investors own include Immunic (IMUX), Trevena (TRVN), AIM ImmunoTech (AIM), Ampio Pharmaceuticals (AMPE), Chimerix (CMRX), CorMedix (CRMD), CTI BioPharma (CTIC), Fortress Biotech (FBIO), Genocea Biosciences (GNCA) and Otonomy (OTIC).

What is Protara Therapeutics' stock symbol?

Protara Therapeutics trades on the NASDAQ under the ticker symbol "TARA."

Who are Protara Therapeutics' major shareholders?

Protara Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.80%), Goldman Sachs Group Inc. (1.36%), Assenagon Asset Management S.A. (0.39%), Renaissance Technologies LLC (0.33%), Prelude Capital Management LLC (0.11%) and Acadian Asset Management LLC (0.10%). Company insiders that own Protara Therapeutics stock include Blaine Davis, Luke M Beshar, Martin Sebastian Olivo, Opaleye Management Inc and Randall Marshall.
View institutional ownership trends for Protara Therapeutics
.

Which institutional investors are selling Protara Therapeutics stock?

TARA stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Renaissance Technologies LLC, Vanguard Group Inc., Acadian Asset Management LLC, Prelude Capital Management LLC, and Simplex Trading LLC.
View insider buying and selling activity for Protara Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Protara Therapeutics stock?

TARA stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A.. Company insiders that have bought Protara Therapeutics stock in the last two years include Blaine Davis, Luke M Beshar, Martin Sebastian Olivo, and Opaleye Management Inc.
View insider buying and selling activity for Protara Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Protara Therapeutics?

Shares of TARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Protara Therapeutics' stock price today?

One share of TARA stock can currently be purchased for approximately $3.12.

How much money does Protara Therapeutics make?

Protara Therapeutics has a market capitalization of $35.11 million. The company earns $-47.25 million in net income (profit) each year or ($3.97) on an earnings per share basis.

How many employees does Protara Therapeutics have?

Protara Therapeutics employs 31 workers across the globe.

What is Protara Therapeutics' official website?

The official website for Protara Therapeutics is www.proteontherapeutics.com.

How can I contact Protara Therapeutics?

Protara Therapeutics' mailing address is 1 LITTLE WEST 12TH STREET, NEW YORK NY, 10014. The company can be reached via phone at (646) 844-0337, via email at [email protected], or via fax at 781-487-6729.

This page was last updated on 5/16/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.